Focused Investment in Growth Areas, R&D and Labor-Saving Initiatives
First written in FY2016. 25 of 31 entries say "Restated". Latest entry: FY2027-H1.
4 other companies' latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「The Group's total research and development expenditure during the interim consolidated accounting period was ¥1,368 million. We remain committed to actively investing in important themes, with a constant focus on returns on investment.」
The Group conducted ¥1,368 million of research and development activities and continues its policy of actively investing in important themes with a focus on returns on investment. - FY2026AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥2,685 million.」
The company continued its R&D investment in cutting-edge important themes, and R&D expenses increased from ¥2,559 million in FY2025 to ¥2,685 million. - FY2026-H1RestatedAnnual report
「The amount spent on R&D activities across the group during the interim consolidated accounting period was ¥1,310 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The group conducted R&D activities costing ¥1,310 million and continued its policy of actively investing in important themes while remaining focused on returns on investment. - FY2025AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥2,559 million. We will continue to remain focused on returns on investment and actively invest in cutting-edge important themes selectively and without waste.」
The company continued its R&D investment in cutting-edge important themes, and R&D expenses increased from ¥2,315 million in FY2024 to ¥2,559 million in FY2025. - FY2025-H1RestatedAnnual report
「The amount spent on R&D activities across the group during the interim consolidated accounting period was ¥1,293 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The group invested ¥1,293 million in R&D activities and continued its policy of actively investing in important themes while remaining focused on returns on investment. - FY2024AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥2,315 million. We will continue to remain focused on returns on investment and actively invest in cutting-edge important themes selectively and without waste.」
The company continued its R&D investment in important themes, bringing R&D expenses for the fiscal year to ¥2,315 million. - FY2024-Q2RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative second quarter period was ¥1,159 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company invested ¥1,159 million in R&D activities and continued its policy of actively investing in important themes while remaining focused on returns on investment. There were no significant changes in its R&D activities. - FY2024-Q1RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative first quarter period was ¥571 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded ¥571 million in R&D activity spending and continued its policy of actively investing in important themes while remaining focused on returns on investment. - FY2023-Q2RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative second quarter period was ¥1,147 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded ¥1,147 million in R&D activity spending and continued its policy of actively investing in important themes while remaining focused on returns on investment. - FY2023-Q1RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative first quarter period was ¥566 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded ¥566 million in group-wide R&D activity spending and continued its policy of actively investing in important themes while remaining focused on returns on investment. - FY2022AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥2,280 million. We will continue to remain focused on returns on investment and actively invest in important themes selectively and without waste.」
The company continued its R&D investment in important themes, bringing R&D expenses for FY2022 to ¥2,280 million. Capital expenditures were also ¥3,341 million, allocated to the Hirakata Chemical Products Plant, Central Research Institute, Hirakata Machinery Plant construction site and other projects. - FY2022-Q3RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative third quarter period was ¥1,655 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded ¥1,655 million in group-wide R&D activity spending and continued its policy of actively investing in important themes while remaining focused on returns on investment. - FY2022-Q2RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative second quarter period was ¥1,091 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded ¥1,091 million in R&D activity spending and continued to actively invest in important themes while remaining focused on returns on investment. - FY2022-Q1RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative first quarter period was ¥527 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded ¥527 million in R&D activity spending and continued to actively invest in important themes while remaining focused on returns on investment. - FY2021-Q3RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative third quarter period was ¥1,587 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded ¥1,587 million in group-wide R&D activity spending and continued to actively invest in important themes while remaining focused on returns on investment. - FY2021-Q2RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative second quarter period was ¥1,059 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company disclosed group-wide R&D activity spending of ¥1,059 million for the cumulative second quarter period, while continuing its policy of actively investing in research and development and remaining focused on returns on investment. - FY2021-Q1RestatedAnnual report
「The amount spent on R&D activities across the group during the cumulative first quarter period was ¥518 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded ¥518 million in group-wide R&D expenses and reaffirmed its policy of continuing to actively invest in important themes while remaining focused on returns on investment. - FY2020-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter period were ¥1,711 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded R&D expenses of ¥1,711 million and reaffirmed its policy of continuing to actively invest in important themes while remaining focused on returns on investment. - FY2020-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter period were ¥1,158 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded R&D expenses of ¥1,158 million and reaffirmed its policy of continuing to actively invest in important themes while remaining focused on returns on investment. - FY2020-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter period were ¥568 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded R&D expenses of ¥568 million and reaffirmed its policy of continuing to actively invest in important themes while remaining focused on returns on investment. - FY2019-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter period were ¥1,633 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded R&D expenses of ¥1,633 million and reaffirmed its policy of continuing to actively invest in important themes while remaining focused on returns on investment. - FY2019-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter period were ¥1,073 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded R&D expenses of ¥1,073 million and reaffirmed its policy of continuing to actively invest in important themes while remaining focused on returns on investment. - FY2019-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter period were ¥538 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company recorded R&D expenses of ¥538 million and reaffirmed its policy of continuing to actively invest in important themes while remaining focused on returns on investment. - FY2018AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥2,092 million. We will continue to remain focused on returns on investment and actively invest in important themes selectively and without waste.」
The company continued its R&D investment in important themes, bringing total R&D expenses for the fiscal year to ¥2,092 million. It also made total capital expenditures of ¥3,919 million. - FY2018-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter period were ¥1,555 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company is continuing its R&D investment in important themes and disclosed R&D expenses of ¥1,555 million for the cumulative third quarter period. - FY2018-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter period were ¥1,019 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company is continuing its policy of actively investing in research and development while remaining focused on returns on investment, and disclosed R&D expenses of ¥1,019 million for the cumulative second quarter period. - FY2018-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter period were ¥495 million. We will continue to remain focused on returns on investment and intend to actively invest in important themes going forward.」
The company is continuing its policy of actively investing in research and development while remaining focused on returns on investment, and disclosed R&D expenses of ¥495 million for the cumulative first quarter period. - FY2017-Q3RestatedAnnual report
「Research and development expenses for the first nine months of the current consolidated fiscal year were ¥1.496 billion. The Company intends to continue investing actively in important themes, with constant attention to returns on investment.」
The company is continuing its policy of actively investing in research and development while remaining focused on returns on investment, and disclosed R&D expenses of ¥1,496 million for the cumulative third quarter period. - FY2017-Q2RestatedAnnual report
「Research and development expenses for the first six months of the current consolidated fiscal year were ¥1 billion. The Company intends to continue investing actively in important themes, with constant attention to returns on investment.」
The policy of investing in research and development continues, and research and development expenses of ¥1 billion were disclosed for the first six months of the current fiscal year. - FY2017-Q1RestatedAnnual report
「Research and development expenses for the first cumulative quarter of the current consolidated fiscal year were ¥497 million. The Company intends to continue investing actively in important themes, with constant attention to returns on investment.」
The policy of investing in research and development continues, and research and development expenses of ¥497 million were disclosed for the current quarter. The Company also states that there has been no material change in its research and development activities. - FY2016First statedAnnual report
「The Group focuses on product fields and research and development fields expected to deliver long-term growth, while also investing to save labor, streamline operations and improve product reliability. Capital investment for the current consolidated fiscal year was ¥2,094,831 thousand.」
Capital investment for the current fiscal year was ¥2.094 billion, including investment in the Central Research Institute, overseas pharmaceutical manufacturing lines and plating processing lines.